1700632877
1700632878
1.骨质疏松症有哪些防范措施？
1700632879
1700632880
2.试述骨质疏松症的药物治疗。
1700632881
1700632882
参考文献
1700632883
1700632884
[1] 徐永清，陆声．骨质疏松性骨折的预防和治疗．创伤外科杂志，2006，8(6).
1700632885
1700632886
[2] McLellan AR, Gallacher SJ. The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture. Osteoporos Int, 2003, 14
:1028-1034.
1700632887
1700632888
[3] 李洲，马宝通．骨质疏松性骨折的预防研究进展．中华临床医学杂志，2007，8(11)
:31-34.
1700632889
1700632890
[4] Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3（cholecalciferol）supplementation on fractures and mortality in men and women living in the community: Randomised double blind controlled trial. BMJ, 2003, 326
:469-472.
1700632891
1700632892
[5] Grant AM, Avenell A, Campbell MK, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people（Randomised Evaluation of Calcium Orvitamin D, RECORD): A randomised placebocontrolled trial. Lancet, 2005, 365
:1621-1628.
1700632893
1700632894
[6] Porthouse J, Cockayne S, King C, et al. Randomised controlled trial of calcium and supplementation with cholecalciferol（vitamin D3）for prevention of fractures in primary care. BMJ, 2005, 330
:1003-1006.
1700632895
1700632896
[7] Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med, 2006, 354
:669-683.
1700632897
1700632898
[8] Boonen S, Rizzoli R, Meunier PJ, et al. The need for clinical guidance in the use of calcium and vitamin D in the mangement of osteoporosis: a consensus report. Osteoporos Int, 2004, 15
:511-519.
1700632899
1700632900
[9] Greenblatt D. Treatment of postmenopausal osteoporosis. Pharmacotherapy, 2005, 25
:574-584.
1700632901
1700632902
[10] Cranney A, Wells G, Willan A, et al. For the Osteoporosis Methodology Group and the Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. Ⅱ. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev, 2002, 23
:508-516.
1700632903
1700632904
[11] Schnitzer T, Bone HG, Crepaldi G, et al. For the Alendronate Once-Weekly Study Group. Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10mg daily in the treatment of osteoporosis. Aging,（MiIano), 2000, 12
:1-12.
1700632905
1700632906
[12] Bone HG, Hosking D, Devogelaer JP, et al. For the Alendronate Phase Ⅲ Osteoporosis Treatment Study Group. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med, 2004, 350
:1189-1199.
1700632907
1700632908
[13] Recker R, Ensrud K, Diem S, et al. Normal bone histomorphometry and 3D microarchitecture after 10 years alendronate treatment of postmenopausal women. J Bone Miner Res, 2004, 19
:45.
1700632909
1700632910
[14] Harris ST, Watts NB, Genant HK, et al. For the Vertebral Efficacy with Risedronate Therapy（VERT）Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. JAMA, 1999, 282
:1344-1352.
1700632911
1700632912
[15] Reginster J, Minne HW, Sorensen OH, et al. For the Vertebral Efficacy with Risedronate Therapy（VERT）Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int, 2000, 11
:83-91.
1700632913
1700632914
[16] Reginster J, Minne HW, Sorensen OH, et al. For the Vertebral Efficacy with Risedronate Therapy（VERT）Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int, 2000, 11
:83-91.
1700632915
1700632916
[17] Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int. 2002, 71
:103-111.
1700632917
1700632918
[18] Greenblatt D. Treatment of postmenopausal osteoporosis. Pharmacotherapy. 2005, 25
:574-584.
1700632919
1700632920
[19] Miller PD. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: The emerging role of intermittent therapy. Clin Ther, 2005, 27
:361-376.
1700632921
1700632922
[20] Barrett J, Worth E, Bauss F, Epstein S. Ibandronate: A clinical pharmacological and pharmacokinetic update. J Clin Pharmacol, 2004, 44
:951-965.
1700632923
1700632924
[21] Chestnut CH III, Skag A, Christiansen C, et al. For the Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe（BONE). EFFects of oral ibandronate administered daily or intermittently on Fracture risk in postmenopausal osteoporosis. J Bone Miner Res, 2004, 19
:1241-1249.
1700632925
1700632926
[22] Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-Year results from the MOBILE study. J Bone Miner Res, 2005, 20
:1315-1322.
[
上一页 ]
[ :1.700632877e+09 ]
[
下一页 ]